December 15, 2017 / 7:33 AM / in 5 months

BRIEF-Tigenix Announces Grant From Mesoblast Of Exclusive Global Patent License In Local Treatment Of Fistulae

Dec 15 (Reuters) - Tigenix Nv:

* MESOBLAST GRANTS TIGENIX AN EXCLUSIVE GLOBAL PATENT LICENSE TO USE ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN THE LOCAL TREATMENT OF FISTULAE (EN)

* AGREEMENT INCLUDES RIGHT FOR CO TO GRANT SUB-LICENSES TO AFFILIATES AND THIRD PARTIES

* MESOBLAST WILL RECEIVE SINGLE DIGIT ROYALTIES ON NET SALES OF CX601

* MESOBLAST WILL RECEIVE UP TO EUR 20 MILLION IN PAYMENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below